| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of 1 Dermatology and 2 Pathology, University of Vienna, Vienna, Austria; 3 Human Cancer Genetics, Ohio State University, Columbus, Ohio; 4 Institute of Molecular Pathology, Vienna, Austria; 5 Department of Obstetrics and Gynecology, University of Vienna and Ludwig Boltzmann Institute of Clinical and Experimental Oncology, Vienna, Austria; and 6 Boehringer Ingelheim Austria, Vienna, Austria
With the objective of discovering novel putative intervention sites for anticancer therapy, we compared transcriptional profiles of breast cancer, lung squamous cell cancer (LSCC), lung adenocarcinoma (LAC), and renal cell cancer (RCC). Each of these tumor types still needs improvement in medical treatment. Our intention was to search for genes not only highly expressed in the majority of patient samples but which also exhibit very low or even absence of expression in a comprehensive panel of 16 critical (vital) normal tissues. To achieve this goal, we combined two powerful technologies, PCR-based cDNA subtraction and cDNA microarrays. Seven subtractive libraries consisting of 
9250 clones were established and enriched for tumor-specific transcripts. These clones, together with 1750 additional tumor-relevant genes, were used for cDNA microarray preparation. Hybridizations were performed using a pool of 16 critical normal tissues as a reference in all experiments. In total, we analyzed 20 samples of breast cancer, 11 of LSCC, 11 of LAC, and 8 of RCC. To select for genes with low or even no expression in normal tissues, expression profiles of 22 different normal tissues were additionally analyzed. Importantly, this tissue-wide expression profiling allowed us to eliminate genes, which exhibit also high expression in normal tissues. Similarly, expression signatures of genes, which are derived from infiltrating cells of the immune system, were eliminated as well. Cluster analysis resulted in the identification of 527 expressed sequence tags specifically up-regulated in these tumors. Gene-wise hierarchical clustering of these clones clearly separated the different tumor types with RCC exhibiting the most homogenous and LAC the most diverse expression profile. In addition to already known tumor-associated genes, the majority of identified genes have not yet been brought into context with tumorigenesis such as genes involved in bone matrix mineralization (OSN, OPN, and OSF-2) in lung, breast, and kidney cancer or genes controlling Ca2+ homeostasis (RCN1,CALCA, S100 protein family). EGLN3, which recently has been shown to be involved in regulation of hypoxia-inducible factor, was found to be highly up-regulated in all RCCs and in half of the LSCCs analyzed. Furthermore, 42 genes, the expression level of which correlated with the overall survival of breast cancer patients, were identified. The gene dendogram clearly separates two groups of genes, those up-regulated such as cyclin B1, TGF-ß3, B-Myb, Erg2, VCAM-1, and CD44 and those down-regulated such as MIG-6, Esp15, and CAK in patients with short survival time.
This article has been cited by other articles:
|
|
 |
|
  N. Jin, S.-N. Cho, M. G. Raso, I. Wistuba, Y. Smith, Y. Yang, J. M. Kurie, R. Yen, C. M. Evans, T. Ludwig, et al. Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis Development, October 1, 2009; 136(19): 3347 - 3356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Jeong, H. S. Lee, K. Y. Lee, L. D. White, R. R. Broaddus, Y.-W. Zhang, G. F. Vande Woude, L. C. Giudice, S. L. Young, B. A. Lessey, et al. Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease PNAS, May 26, 2009; 106(21): 8677 - 8682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mannefeld, E. Klassen, and S. Gaubatz B-MYB Is Required for Recovery from the DNA Damage-Induced G2 Checkpoint in p53 Mutant Cells Cancer Res., May 1, 2009; 69(9): 4073 - 4080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Miller, D. L. Shattuck, E. Q. Ingalla, L. Yen, A. D. Borowsky, L. J.T. Young, R. D. Cardiff, K. L. Carraway III, and C. Sweeney Suppression of the Negative Regulator LRIG1 Contributes to ErbB2 Overexpression in Breast Cancer Cancer Res., October 15, 2008; 68(20): 8286 - 8294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Raulic, Y. Ramos-Valdes, and G. E DiMattia Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro J. Endocrinol., June 1, 2008; 197(3): 517 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Huang, H.-C. Cheng, R. Isom, C.-S. Chen, R. A. Levine, and B. U. Pauli Protein Kinase C{epsilon} Mediates Polymeric Fibronectin Assembly on the Surface of Blood-borne Rat Breast Cancer Cells to Promote Pulmonary Metastasis J. Biol. Chem., March 21, 2008; 283(12): 7616 - 7627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wen, L. Andrejka, J. Ashton, R. Karess, and J. S. Lipsick Epigenetic regulation of gene expression by Drosophila Myb and E2F2-RBF via the Myb-MuvB/dREAM complex Genes & Dev., March 1, 2008; 22(5): 601 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Esseghir, A. Kennedy, P. Seedhar, A. Nerurkar, R. Poulsom, J. S. Reis-Filho, and C. M. Isacke Identification of NTN4, TRA1, and STC2 as Prognostic Markers in Breast Cancer in a Screen for Signal Sequence Encoding Proteins Clin. Cancer Res., June 1, 2007; 13(11): 3164 - 3173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Liang, Y. Li, X. Be, S. Howes, and W. Liu Detecting and profiling tissue-selective genes Physiol Genomics, September 14, 2006; 26(2): 158 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-T. Le, E. Chen, A. Salim, H. Cao, C. S. Kong, R. Whyte, J. Donington, W. Cannon, H. Wakelee, R. Tibshirani, et al. An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non-Small Cell Lung Cancers Clin. Cancer Res., March 1, 2006; 12(5): 1507 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pante, J. Thompson, F. Lamballe, T. Iwata, I. Ferby, F. A. Barr, A. M. Davies, F. Maina, and R. Klein Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growth J. Cell Biol., October 24, 2005; 171(2): 337 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Itoh, K. Karlsberg, I. Kijima, Y.-C. Yuan, D. Smith, J. Ye, and S. Chen Letrozole-, Anastrozole-, and Tamoxifen-Responsive Genes in MCF-7aro Cells: A Microarray Approach Mol. Cancer Res., April 1, 2005; 3(4): 203 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hervouet, J. Demont, P. Pecina, A. Vojtiskova, J. Houstek, H. Simonnet, and C. Godinot A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis Carcinogenesis, March 1, 2005; 26(3): 531 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Zucchi, E. Mento, V. A. Kuznetsov, M. Scotti, V. Valsecchi, B. Simionati, E. Vicinanza, G. Valle, S. Pilotti, R. Reinbold, et al. Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis PNAS, December 28, 2004; 101(52): 18147 - 18152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Lipsick synMuv verite--Myb comes into focus Genes & Dev., December 1, 2004; 18(23): 2837 - 2844. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
